8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2009

AMICUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-33497	71-0869350
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6 Cedar Brook Drive, Cranbury, NJ	08512
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On October 28, 2009, Margaret G. McGlynn, R.Ph. was elected to the Board of Directors of Amicus Therapeutics, Inc. (the “Company”). Ms. McGlynn will join the Board of Directors as an independent director. Ms. McGlynn has not yet been appointed to any Board committees.

There is no arrangement or understanding between Ms. McGlynn and any other person pursuant to which Ms. McGlynn was elected as director of the Company. There are no relationships or transactions in which Ms. McGlynn has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing Ms. McGlynn’s election is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits .

99.1 Press Release, dated November 3, 2009

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMICUS THERAPEUTICS, INC.
Date: November 3, 2009	By:	/s/ GEOFFREY P. GILMORE
		Name:	Geoffrey P. Gilmore
		Title:	Senior Vice President and General Counsel

3

EXHIBIT INDEX

Exhibit No.		Description
	99.1	Press Release, dated November 3, 2009

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph.,
to Board of Directors

Cranbury, NJ, November 3, 2009 — Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of Margaret G. McGlynn, R.Ph., to its Board of Directors. Ms. McGlynn most recently served as President of Vaccines and Infectious Diseases for Merck & Co., Inc.

John F. Crowley, President and CEO of Amicus Therapeutics stated, “Margie’s vast industry expertise and insight will be invaluable to Amicus as we execute on our key strategic priorities and continue our focus on building shareholder value with our innovative technologies. We are very pleased to welcome her to our Board.”

About Margaret G. McGlynn, R.Ph.
Margaret McGlynn recently retired from Merck and Co., Inc. after more than 26 years of service. Her most recent role was President of Merck Vaccines and Infectious Diseases from 2005 through November 2009. McGlynn joined Merck in 1983 and served in a variety of marketing, sales and managed care roles. In addition to her position at Merck, McGlynn serves as a member of the Board of Directors for Air Products and Chemicals. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences and recently served as a member of the Global Alliance for Vaccine Immunization (GAVI) Board and Executive Committee. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.

About Amicus Therapeutics
Amicus Therapeutics is a late-stage biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Amicus is initially targeting lysosomal storage disorders and diseases of neurodegeneration with unmet medical needs.

CONTACTS:
Jenene Thomas
Director, Investor Relations
(609) 662-5084

FOLD —G